ValueQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25TTMSelling/general/admin expenses4.71 M5.83 M3.33 M3.04 M3.69 M15.89 MResearch & development8.81 M8.96 M5.5 M5.78 M5.01 M25.24 M영업 이익-13.93 M-25.7 M1.49 M-8.66 M-5.29 M-38.16 MNon-Operating Income, Total1.4 M1.17 M1.03 M917 K1.53 M4.66 MInterest expense, net of interest capitalized30 K28 K28 K23 K18 K97 KNon-Operating Income, excl. Interest Expenses1.37 M1.15 M1.01 M894 K1.52 M4.56 MUnusual income/expense——————Pretax income-70 M-24.55 M2.5 M-7.76 M-33.5 M-63.33 MEquity in earnings——————Taxes1.12 M———-8.01 M—Non-controlling/minority interest——————After tax other income/expense——————Net income before discontinued operations-12.53 M-24.53 M2.52 M-7.74 M-3.76 M-33.5 MDiscontinued operations——————Net income-12.53 M-24.53 M2.52 M-7.74 M-3.76 M-33.5 MDilution adjustment——————Preferred dividends——————Diluted net income available to common stockholders-12.53 M-24.53 M2.52 M-7.74 M-3.76 M-33.5 MBasic earnings per share (Basic EPS)-0.07-0.130.01-0.04-0.01-0.17Diluted earnings per share (Diluted EPS)-0.07-0.130.01-0.04-0.01-0.17Average basic shares outstanding185.61 M190.71 M191.55 M191.78 M191.6 M765.64 MDiluted shares outstanding185.61 M190.71 M192.4 M191.78 M191.6 M766.49 MEBITDA-14.86 M-25.37 M1.5 M-8.65 M-5.71 M-38.23 MEBIT-13.93 M-25.7 M1.49 M-8.66 M-5.29 M-38.16 MCost of revenue——————Other cost of goods sold——————Depreciation & amortization (cash flow)-923 K330 K11 K11 K-422 K-70 K
Arbutus Biopharma Corporation
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
It is headquartered in Warminster, Pennsylvania. The company was formerly known as Tekmira, which was spun out of Inex Pharmaceuticals in 2007.